Literature DB >> 33444735

Plasma Proteomes Can Be Reidentifiable and Potentially Contain Personally Sensitive and Incidental Findings.

Philipp E Geyer1, Sebastian Porsdam Mann2, Peter V Treit3, Matthias Mann4.   

Abstract

The goal of clinical proteomics is to identify, quantify, and characterize proteins in body fluids or tissue to assist diagnosis, prognosis, and treatment of patients. In this way, it is similar to more mature omics technologies, such as genomics, that are increasingly applied in biomedicine. We argue that, similar to those fields, proteomics also faces ethical issues related to the kinds of information that is inherently obtained through sample measurement, although their acquisition was not the primary purpose. Specifically, we demonstrate the potential to identify individuals both by their characteristic, individual-specific protein levels and by variant peptides reporting on coding single nucleotide polymorphisms. Furthermore, it is in the nature of blood plasma proteomics profiling that it broadly reports on the health status of an individual-beyond the disease under investigation. Finally, we show that private and potentially sensitive information, such as ethnicity and pregnancy status, can increasingly be derived from proteomics data. Although this is potentially valuable not only to the individual, but also for biomedical research, it raises ethical questions similar to the incidental findings obtained through other omics technologies. We here introduce the necessity of-and argue for the desirability for-ethical and human-rights-related issues to be discussed within the proteomics community. Those thoughts are more fully developed in our accompanying manuscript. Appreciation and discussion of ethical aspects of proteomic research will allow for deeper, better-informed, more diverse, and, most importantly, wiser guidelines for clinical proteomics.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  alleles; biomarker discovery; clinical proteomics; ethics

Mesh:

Substances:

Year:  2021        PMID: 33444735      PMCID: PMC7950134          DOI: 10.1074/mcp.RA120.002359

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  5 in total

Review 1.  Advances and Utility of the Human Plasma Proteome.

Authors:  Eric W Deutsch; Gilbert S Omenn; Zhi Sun; Michal Maes; Maria Pernemalm; Krishnan K Palaniappan; Natasha Letunica; Yves Vandenbrouck; Virginie Brun; Sheng-Ce Tao; Xiaobo Yu; Philipp E Geyer; Vera Ignjatovic; Robert L Moritz; Jochen M Schwenk
Journal:  J Proteome Res       Date:  2021-10-21       Impact factor: 5.370

2.  Progress Identifying and Analyzing the Human Proteome: 2021 Metrics from the HUPO Human Proteome Project.

Authors:  Gilbert S Omenn; Lydie Lane; Christopher M Overall; Young-Ki Paik; Ileana M Cristea; Fernando J Corrales; Cecilia Lindskog; Susan Weintraub; Michael H A Roehrl; Siqi Liu; Nuno Bandeira; Sudhir Srivastava; Yu-Ju Chen; Ruedi Aebersold; Robert L Moritz; Eric W Deutsch
Journal:  J Proteome Res       Date:  2021-10-20       Impact factor: 5.370

3.  Ethical Principles, Constraints and Opportunities in Clinical Proteomics.

Authors:  Sebastian Porsdam Mann; Peter V Treit; Philipp E Geyer; Gilbert S Omenn; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2021-01-14       Impact factor: 5.911

4.  Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma.

Authors:  Lorenz Nierves; Jian Guo; Siyuan Chen; Janice Tsui; Anuli C Uzozie; Jonathan W Bush; Tao Huan; Philipp F Lange
Journal:  Exp Hematol Oncol       Date:  2022-09-15

Review 5.  A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action.

Authors:  Seanantha S Baros-Steyl; Saba Al Heialy; Ahlam H Semreen; Mohammad H Semreen; Jonathan M Blackburn; Nelson C Soares
Journal:  Proteomics       Date:  2022-07-15       Impact factor: 5.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.